Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: Results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up
MetadataShow full item record
Trial 24, one of three ongoing trials in the Early Prostate Cancer programme, is evaluating the efficacy and tolerability of bicalutamide (Casodex) 150 mg following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with early, non-metastatic prostate cancer. At 7 years' median follow-up, addition of bicalutamide significantly improved objective progression-free survival (PFS) for patients with locally advanced disease, reducing the risk of progression by 34% versus standard care alone (hazard ratio 0.66; 95% confidence interval 0.55, 0.79; P<0.001). In localized disease, a significant difference in objective PFS was not found. There was no significant difference in overall survival.
Please cite this item using this persistent URLhttp://hdl.handle.net/10019.1/14360
Showing items related by title, author, creator and subject.
Bicalutamide ('Casodex') 150mg in addition to standard care in patients with nonmetastatic prostate cancer: Updated results from a randomised double-blind phase III study (median follow-up 5.1y) in the early prostate cancer programme Wirth M.; Tyrrell C.; Delaere K.; Sanchez-Chapado M.; Ramon J.; Wallace D.M.A.; Hetherington J.; Pina F.; Heyns C.; Borchers T.; Morris T.; Armstrong J. (2005)Trial 24 is one of three placebo-controlled trials within the ongoing bicalutamide ('Casodex'+) Early Prostate Cancer (EPC) programme evaluating bicalutamide 150mg/day in addition to radical prostatectomy, radiotherapy or ...
Wessels G.; Hesseling P.B. (1996)The data of a survey undertaken to record all cases of childhood cancer in Namibia from 1983 to 1988 were analyzed to estimate 5-year survival rates. The projected survival rate for 150 children with cancer was 37% with ...
A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen Ruff P.; Vorobiof D.A.; Jordaan J.P.; Demetriou G.S.; Moodley S.D.; Nosworthy A.L.; Werner I.D.; Raats J.; Burgess L.J. (2009)Purpose: To determine if concomitant administration of docetaxel plus zosuquidar.3HC1 can prolong progression-free survival in patients with metastatic breast cancer. Methods: A randomized, double-blind, multicenter, ...